Nuveen Asset Management LLC Lowers Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Nuveen Asset Management LLC cut its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 13.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 141,298 shares of the company’s stock after selling 22,400 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.14% of Day One Biopharmaceuticals worth $1,790,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. R Squared Ltd acquired a new position in Day One Biopharmaceuticals in the 4th quarter valued at $31,000. Tower Research Capital LLC TRC lifted its stake in Day One Biopharmaceuticals by 911.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company’s stock worth $135,000 after acquiring an additional 9,603 shares during the last quarter. E Fund Management Co. Ltd. purchased a new position in Day One Biopharmaceuticals in the fourth quarter worth approximately $143,000. KLP Kapitalforvaltning AS acquired a new stake in Day One Biopharmaceuticals during the fourth quarter worth approximately $150,000. Finally, Optimize Financial Inc acquired a new stake in Day One Biopharmaceuticals during the fourth quarter worth approximately $196,000. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Insider Activity at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 13,964 shares of Day One Biopharmaceuticals stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $6.26, for a total transaction of $87,414.64. Following the transaction, the chief executive officer now owns 145,737 shares of the company’s stock, valued at $912,313.62. The trade was a 8.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Charles N. York II sold 4,282 shares of the stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $6.26, for a total value of $26,805.32. Following the completion of the transaction, the chief financial officer now owns 265,231 shares in the company, valued at $1,660,346.06. This represents a 1.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 26,725 shares of company stock worth $167,299 over the last ninety days. 6.20% of the stock is currently owned by corporate insiders.

Day One Biopharmaceuticals Trading Down 0.4%

DAWN stock opened at $6.98 on Wednesday. The company has a market capitalization of $707.51 million, a P/E ratio of -6.78 and a beta of -1.24. The firm has a 50 day simple moving average of $6.99 and a 200-day simple moving average of $10.08. Day One Biopharmaceuticals, Inc. has a twelve month low of $6.08 and a twelve month high of $16.76.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.11. The firm had revenue of $30.76 million for the quarter, compared to analyst estimates of $30.28 million. On average, research analysts predict that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current year.

Analyst Upgrades and Downgrades

DAWN has been the subject of several research reports. Needham & Company LLC reduced their price target on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. The Goldman Sachs Group reduced their target price on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating on the stock in a report on Tuesday, March 25th. HC Wainwright reiterated a “buy” rating and set a $36.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. JPMorgan Chase & Co. dropped their target price on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating for the company in a research report on Wednesday, March 5th. Finally, Wedbush restated an “outperform” rating and issued a $25.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, May 7th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $30.57.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.